BioSpace News Archive

Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi®

Allied BioScience Plans to Expand Team to Support National Distribution of First-of-its-kind Residual Antimicrobial Coating, Extension of Product Portfolio

Dr. Auerbach will further strengthen OCON’s efforts in expanding and developing ground-breaking intrauterine solutions to better women’s health for world-wide markets including the USA

Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Dakota ACDF™ Standalone System in the treatment of degenerative disc disease (DDD).

Vertimass is proud to announce that its President and Chief Executive Officer Dr. Charles Wyman was recently ranked as the number 11 scientist globally in biotechnology in Stanford University’s list of the World’s Top 2% of Scientists.

Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11, 2021 at 3:30 p.m. ET.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results. Conference Call and Webcast Details

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that company management will participate at two upcoming investor conferences:

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies.